Genome Sequencing in Refractory Breast Cancer to Molecular Targeted Therapy and Young Breast Cancer
- Conditions
- Breast Cancer
- Registration Number
- NCT02597179
- Lead Sponsor
- Samsung Medical Center
- Brief Summary
The purpose of this study is to investigate and analyse genomic profiles in patient with breast cancer who failed standard treatment, refractory and young breast cancer.
- Detailed Description
The hypothesis is that genomic profiling measured by CancerSCAN, cfDNA, Whole exome sequencing (WES), Whole transcriptome sequencing (WTS), FACS(Fluorescence-Activated Cell Sorting), cytokine and immunologic signature analysis would be helpful to find out tolerance for chemotherapy and innovate new therapeutic strategies.
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 350
Inclusion Criteria
- Histologically or cytologically confirmed breast cancer that is either metastatic or young breast cancer(≤ 40 years of age).
- HER2 positive patient who failed HER2 target therapy including trastuzumab with feasible biopsy site.
- Triple Negative Breast Cancer patient who failed standard therapy with feasible biopsy site.
- Hormone Receptor positive patient who failed standard therapy with feasible biopsy site.
- Age ≥ 21 years
- Written informed consent
Read More
Exclusion Criteria
- No feasible biopsy site
- No written informed consent
Read More
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Number of Participants With Mutated Genes and/or Abnormal Gene expression and/or Different Immune signature That Affect to Treatment Outcome. 1 year
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Samsung Medical Center
🇰🇷Seoul, Gangnam-Gu, Korea, Republic of